Nalorphine hydrobromide

application：SB265610 has been used:as a cysteine-amino acid-cysteine (CXC)-chemokine receptor type 2 (CXCR2) antagonist to study its effects on the binding of chemokine with G-protein coupled receptors (GPCR)as a CX-chemokine receptor type 1 (CXCR1)

application：SB265610 has been used:as a cysteine-amino acid-cysteine (CXC)-chemokine receptor type 2 (CXCR2) antagonist to study its effects on the binding of chemokine with G-protein coupled receptors (GPCR)as a CX-chemokine receptor type 1 (CXCR1)

application：SB265610 has been used:as a cysteine-amino acid-cysteine (CXC)-chemokine receptor type 2 (CXCR2) antagonist to study its effects on the binding of chemokine with G-protein coupled receptors (GPCR)as a CX-chemokine receptor type 1 (CXCR1)

application：SB265610 has been used:as a cysteine-amino acid-cysteine (CXC)-chemokine receptor type 2 (CXCR2) antagonist to study its effects on the binding of chemokine with G-protein coupled receptors (GPCR)as a CX-chemokine receptor type 1 (CXCR1)

application：SB265610 has been used:as a cysteine-amino acid-cysteine (CXC)-chemokine receptor type 2 (CXCR2) antagonist to study its effects on the binding of chemokine with G-protein coupled receptors (GPCR)as a CX-chemokine receptor type 1 (CXCR1)

application：SB265610 has been used:as a cysteine-amino acid-cysteine (CXC)-chemokine receptor type 2 (CXCR2) antagonist to study its effects on the binding of chemokine with G-protein coupled receptors (GPCR)as a CX-chemokine receptor type 1 (CXCR1)